In AD, the most advanced RNA-based therapeutic is based on translational inhibition of tau mRNA using an ASO-based strategy (NCT03186989, BIIB080, IONISMAPTRX), and is currently a clinical phase I/II trial study. Here, MAPT is linked to Alzheimer disease.